IPO - BIOLARGO, INC.

Form Type: 424B4

Filing Date: 2025-06-11

Corporate Action: Ipo

Type: New

Accession Number: 000143774925020012

Filing Summary: BioLargo, Inc. is offering 34,888,449 shares of common stock, with 30,286,473 shares issuable upon the exercise of warrants. The warrants were purchased by selling stockholders in private transactions and carry exercise prices from $0.18 to $0.3264. The company anticipates receiving up to $7,969,461 in gross proceeds if all warrants are exercised. The document outlines that BioLargo will not receive proceeds from direct sales; however, proceeds from warrant exercises will be used for working capital and debt repayment. Risks associated with the investment involve significant cash requirements and the potential for ongoing financial losses. The company has been quoted on the OTCQX stock market since January 23, 2008, under the symbol 'BLGO'. This prospectus includes cautionary forward-looking statements and a substantial risk factor discussion for potential investors. The last reported sale price of the company's stock on June 9, 2025, was $0.205, and the document emphasizes the speculative nature of investing in BioLargo's common stock.

Form Type: 424B4

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000143774925013152

Filing Summary: BioLargo, Inc. filed a Form 424B4 registration statement on April 25, 2025, to register the sale of 25,507,789 shares of its common stock, par value $0.00067 per share. The offering is being conducted by Lincoln Park Capital Fund, LLC, which is the selling stockholder, as a part of the Purchase Agreement dated December 13, 2022. Under this agreement, Lincoln Park has the right to purchase common stock up to an aggregate of $10 million over time. BioLargo is not selling any shares or receiving proceeds from this offering, and its plan includes potential sales to Lincoln Park which could yield up to an additional $9,076,580 in proceeds, contingent upon market conditions. As of the filing date, there are 301,775,373 shares outstanding, and upon issuance of the newly registered shares, total outstanding shares could rise to 327,135,968. The registration of shares is intended to facilitate BioLargo’s ability to fund its operations through sales to Lincoln Park but involves risks associated with dilution and ongoing losses. Key products highlighted include innovative technologies focused on environmental solutions, and the document stresses the high risks associated with investments in its common stock, characterizing it as a penny stock trading on the OTC Markets under the symbol 'BLGO'.